We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+4.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.49B
AUM Growth
+$287M
(+6.8%)
Cap. Flow
+$532M
Cap. Flow
% of AUM
11.84%
Top 10 Holdings %
Top 10 Hldgs %
50.53%
Holding
128
New
23
Increased
12
Reduced
25
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Design Therapeutics
DSGN
|
+$173M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$75.9M |
| 3 |
Novavax
NVAX
|
+$49.8M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$43.3M |
| 5 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$42.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beam Therapeutics
BEAM
|
+$71.6M |
| 2 |
VIE
Viela Bio, Inc. Common Stock
VIE
|
+$51.4M |
| 3 |
Immunovant
IMVT
|
+$32.3M |
| 4 |
CRISPR Therapeutics
CRSP
|
+$30.6M |
| 5 |
Kura Oncology
KURA
|
+$21.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75% |
| 2 | Financials | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares Russell 2000 ETF
IWM
$79.1B
| $442M | 9.84% |
2,000,000
+1,500,000
| +300% | +$328M |
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $396M | 8.83% |
1,000,000
+500,000
| +100% | +$193M |
|
3
Atea Pharmaceuticals
AVIR
$370M
| $396M | 8.82% |
6,411,355
| – | – |
|
|
TPTX
4
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $260M | 5.8% |
2,750,000
+357,703
| +15% | +$42.5M |
|
|
5
Design Therapeutics
DSGN
$751M
| $146M | 3.26% |
+5,114,850
| New | +$173M |
|
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
| $136M | 3.02% |
1,000,000
-500,000
| -33% | -$74.9M |
|
7
BridgeBio Pharma
BBIO
$16.4B
| $134M | 2.98% |
2,168,909
-96,853
| -4% | -$6.34M |
|
|
FMTX
8
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $132M | 2.95% |
4,720,000
+260,000
| +6% | +$9.38M |
|
9
Revolution Medicines
RVMD
$38.5B
| $116M | 2.58% |
2,525,000
+29,934
| +1% | +$1.34M |
|
10
BioAtla
BCAB
$5.34M
| $110M | 2.45% |
43,841
-2,000
| -4% | -$5.13M |
|
11
Olema Pharmaceuticals
OLMA
$977M
| $105M | 2.34% |
3,195,544
| – | – |
|
12
C4 Therapeutics
CCCC
$389M
| $92.1M | 2.05% |
2,490,065
| – | – |
|
|
APLS
13
DELISTED
Apellis Pharmaceuticals
APLS
| $80.1M | 1.78% |
1,866,108
| – | – |
|
|
14
Edgewise Therapeutics
EWTX
$4.28B
| $74.3M | 1.66% |
+2,340,914
| New | +$75.9M |
|
15
ALX Oncology
ALXO
$262M
| $65M | 1.45% |
881,770
| – | – |
|
16
Zymeworks
ZYME
$1.62B
| $63.2M | 1.41% |
2,000,000
+800,000
| +67% | +$32.5M |
|
17
Rocket Pharmaceuticals
RCKT
$343M
| $60.7M | 1.35% |
1,368,550
| – | – |
|
18
Omeros
OMER
$845M
| $58.7M | 1.31% |
3,300,030
-699,970
| -17% | -$13.6M |
|
19
Stoke Therapeutics
STOK
$1.84B
| $55.8M | 1.24% |
1,437,807
| – | – |
|
20
Tarsus Pharmaceuticals
TARS
$2.55B
| $55.3M | 1.23% |
1,714,269
| – | – |
|
|
RNAM
21
DELISTED
Avidity Biosciences
RNAM
| $53.8M | 1.2% |
2,464,545
-2
| -0% | -$49 |
|
22
Aclaris Therapeutics
ACRS
$715M
| $50.4M | 1.12% |
+2,000,000
| New | +$39.1M |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $47.1M | 1.05% |
275,000
-50,000
| -15% | -$9.9M |
|
|
24
Novavax
NVAX
$1.21B
| $45.3M | 1.01% |
+250,000
| New | +$49.8M |
|
|
CCXI
25
DELISTED
ChemoCentryx, Inc.
CCXI
| $43.6M | 0.97% |
850,000
-350,000
| -29% | -$21.1M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q1 2021 Portfolio in Review
As of Q1 2021, Cormorant Asset Management held 128 positions worth $4.49B, up 6.8% from $4.2B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Cormorant Asset Management deployed $532M of net new capital in Q1 2021, opening 23 new positions and adding to 12 existing holdings. Its largest new stake was Design Therapeutics: 5,114,850 shares worth $146M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Beam Therapeutics, an estimated $71.6M trimmed.
- Cormorant Asset Management's largest Q1 2021 buy was Design Therapeutics: 5,114,850 shares worth $146M.
- Cormorant Asset Management added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2021, an estimated $42.5M increase.
- Cormorant Asset Management's biggest Q1 2021 reduction was Beam Therapeutics, cutting an estimated $71.6M.
- Cormorant Asset Management fully exited Viela Bio, Inc. Common Stock in Q1 2021, selling an estimated $51.4M.
- Cormorant Asset Management's ten largest holdings make up 51% of its $4.49B portfolio in Q1 2021.
- Cormorant Asset Management opened 23 new positions and closed 8 in Q1 2021.
- Cormorant Asset Management's portfolio value rose 6.8% quarter-over-quarter to $4.49B.
Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.